• Market

Eisai’s New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration

For Adjunctive Treatment of Partial Onset Seizures Tokyo, January 05, 2019: Eisai Co., Ltd. announced that its in-house discovered and…